Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash Flows From Operating Activities:
Net loss	$ (91,248)	$ (69,770)	$ (52,642)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	27,972	26,492	31,869
Stock-based compensation	15,139	13,670	13,941
Accretion of debt discount	4,890	5,710	5,250
Amortization of deferred financing costs, recorded to interest expense on 2018 Convertible Notes (Note 15)	567	696	662
Bad debt (recovery) expense	(17)	57	0
Unrealized foreign currency exchange gain	(23)	(153)	(157)
Loss on 2018 Convertible Note purchase (Note 15)	845	25	0
Change in cash surrender value of corporate owned life insurance	(418)	(137)	0
Income tax recognition on unrealized gain on available-for-sale securities	(9,651)	(2,217)	0
Impairment of intangible assets (Note 3(g))	0	0	7,160
Change in fair value of contingent consideration related to the Talon and EVOMELA acquisitions (Note 10)	4,957	649	(676)
Research and development expense	0	2,419	0
Changes in operating assets and liabilities:
Accounts receivable, net	7,694	(9,494)	40,245
Other receivables	3,663	6,895	(7,017)
Inventories	4,318	(5,800)	1,863
Prepaid expenses	(6,137)	(423)	(446)
Other assets	1,573	(2,043)	(1,731)
Accounts payable and other accrued obligations	5,518	(4,033)	(28,298)
Accrued payroll and benefits	280	790	(233)
FOLOTYN development liability	(744)	(1,556)	(1,100)
Acquisition-related contingent obligations	0	(1,300)	0
Deferred revenue	593	(2,985)	(3,511)
Deferred tax liabilities	(5,237)	(104)	210
Other long-term liabilities	(3,389)	2,153	1,355
Net cash (used in) provided by operating activities	(38,855)	(40,459)	6,744
Cash Flows From Investing Activities:
Purchases of property and equipment	(465)	(78)	(223)
Payment for corporate-owned life insurance premiums	(601)	(601)	0
Purchase of equity securities (Note 11)	(15)	0	0
Proceeds from sale of available-for-sale securities	0	0	3,061
Net cash (used in) provided by investing activities	(1,081)	(679)	2,838
Cash Flows From Financing Activities:
Proceeds from exercise of stock options	5,477	203	1,482
Proceeds from sale of stock under employee stock purchase plan	1,010	668	627
Purchase and retirement of restricted stock to satisfy employees' tax liability at vesting	(4,331)	(1,397)	(638)
Payment of contingent consideration related to EVOMELA acquisition (Note 10(b))	0	(4,700)	0
Proceeds from common shares sold under an at-market-issuance sales agreement (Note 7)	128,272	73,869	0
Purchase of 2018 Convertible Notes (Note 15)	(27,500)	(9,014)	0
Purchase of warrants related to the conversion hedge of 2018 Convertible Notes (Note 15)	(27,189)	(330)	0
Proceeds from sale of call options related to the conversion hedge of 2018 Convertible Notes (Note 15)	32,982	351	0
Dividends paid upon conversion of Series E Convertible Voting Preferred Stock (Note 7)	0	(6)	0
Net cash provided by financing activities	108,721	59,644	1,471
Effect of exchange rates on cash and equivalents	316	(25)	(1,254)
Net increase in cash and cash equivalents	69,101	18,481	9,799
Cash and cash equivalents — beginning of year	158,222	139,741	129,942
Cash and cash equivalents — end of year	227,323	158,222	139,741
Supplemental Disclosure of Cash Flow Information:
Cash paid for income taxes	17	11	335
Cash paid for interest	$ 2,692	$ 3,300	$ 3,300